G R Hudes

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi Phase I clinical and pharmacologic trial of intravenous estramustine phosphate
    Gary Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 20:1115-27. 2002
  2. ncbi Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
    G R Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    J Clin Oncol 15:3156-63. 1997
  3. ncbi Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies
    G R Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 6:3071-80. 2000
  4. ncbi Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells
    S Ranganathan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Br J Cancer 85:735-40. 2001
  5. ncbi Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents
    S Ranganathan
    Department of Medicine, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Biochim Biophys Acta 1395:237-45. 1998
  6. ncbi Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells
    S Ranganathan
    Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Br J Cancer 77:562-6. 1998
  7. ncbi Paclitaxel and docetaxel in prostate cancer
    C Obasaju
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Hematol Oncol Clin North Am 15:525-45. 2001
  8. ncbi Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens
    P J O'Dwyer
    Fox Chase Cancer Center, Philadelphia, PA 19111
    J Natl Cancer Inst 83:1235-40. 1991
  9. ncbi Phase II evaluation of menogaril in advanced prostate cancer: Eastern Cooperative Oncology Group EST P-A885
    C Obasaju
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Am J Clin Oncol 24:150-4. 2001
  10. ncbi Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group
    B J Giantonio
    University of Pennsylvania, Philadelphia, USA
    Invest New Drugs 19:89-92. 2001

Collaborators

Detail Information

Publications23

  1. ncbi Phase I clinical and pharmacologic trial of intravenous estramustine phosphate
    Gary Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 20:1115-27. 2002
    ..To determine the dose-limiting toxicities, maximum-tolerated dose, and pharmacokinetics of intravenous estramustine phosphate (IV EMP)...
  2. ncbi Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
    G R Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    J Clin Oncol 15:3156-63. 1997
    ..To evaluate the antitumor activity of 96-hour paclitaxel and daily oral estramustine phosphate (EMP) in patients with metastatic hormone-refractory prostate cancer (HRPC)...
  3. ncbi Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies
    G R Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 6:3071-80. 2000
    ..o. three times daily is well tolerated on a 14-day on/14-day off dosing schedule. Inhibition of p21ras function in humans is not likely to occur after POH administration at safe doses of the present oral formulation...
  4. ncbi Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells
    S Ranganathan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Br J Cancer 85:735-40. 2001
    ..These results highlight the difficulty in isolating the contribution of single tubulin isotypes in drug response studies...
  5. ncbi Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents
    S Ranganathan
    Department of Medicine, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Biochim Biophys Acta 1395:237-45. 1998
    ..Also, the complete coding sequence of human betaIII tubulin reported here will provide molecular tools for future investigations...
  6. ncbi Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells
    S Ranganathan
    Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Br J Cancer 77:562-6. 1998
    ....
  7. ncbi Paclitaxel and docetaxel in prostate cancer
    C Obasaju
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Hematol Oncol Clin North Am 15:525-45. 2001
    ..Pharmacokinetic and pharmacodynamic studies will play a key role in the development of future taxane-based therapies for prostate cancer...
  8. ncbi Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens
    P J O'Dwyer
    Fox Chase Cancer Center, Philadelphia, PA 19111
    J Natl Cancer Inst 83:1235-40. 1991
    ..Tumor levels of PRPP decreased between 12 hours and 24 hours in nine (56%) of 16 patients. This time course indicates that MMPR should be administered at the beginning of the 24-hour infusion of 5-FU...
  9. ncbi Phase II evaluation of menogaril in advanced prostate cancer: Eastern Cooperative Oncology Group EST P-A885
    C Obasaju
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Am J Clin Oncol 24:150-4. 2001
    ..Because of appreciable toxicity and limited antitumor activity, further study of menogaril cannot be recommended in hormone-refractory prostate cancer...
  10. ncbi Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group
    B J Giantonio
    University of Pennsylvania, Philadelphia, USA
    Invest New Drugs 19:89-92. 2001
    ..Any grade fever occurred in 10 patients (25.6%) and any grade chills occurred in 9 patients (23.1%). CONCLUSION: Poly ICLC at this dose and schedule is well tolerated in both patient populations and is inactive in renal carcinoma...
  11. ncbi Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance
    S Ranganathan
    Department of Medicine, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 56:2584-9. 1996
    ..These results indicate that overexpression of specific beta-tubulin isotypes may play a role in the cellular defense against EM and other antimicrotubule agents...
  12. ncbi Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma
    Michael E Burczynski
    Molecular Profiling and Biomarker Discovery, Wyeth Research, 1 Burtt Road, Andover, MA 01810, USA
    Clin Cancer Res 11:1181-9. 2005
    ....
  13. ncbi Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    Gary Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    N Engl J Med 356:2271-81. 2007
    ..Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease...
  14. ncbi Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel
    Tomasz M Beer
    Department of Medicine, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    Invest New Drugs 25:565-70. 2007
    ..6%). One subject (2.6%) had a grade 4 treatment peripheral motor neuropathy. Further study of this dose and schedule of KOS-862 in this patient population cannot be recommended due to both lack of activity and excessive toxicity...
  15. ncbi The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician
    Robert G Uzzo
    Department of Surgical Oncology, Division of Urology, Fox Chase Cancer Center, Temple University School of Medicine, 7701 Burholme Avenue, Room C308, Philadelphia, PA 19111, USA
    Urol Clin North Am 30:423-36. 2003
    ..These studies must be correlated in a rigorous fashion to clinical parameters and outcomes. Progress against this elusive tumor will require a continuous translational dialogue between laboratory and clinical investigators...
  16. ncbi Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data
    Karim Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 8:994-1000. 2007
    ..We aimed to assess whether combining estramustine with chemotherapy increases survival in patients with castration-refractory prostate cancer...
  17. ncbi Survival associated with treatment vs observation of localized prostate cancer in elderly men
    Yu Ning Wong
    Division of Population Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    JAMA 296:2683-93. 2006
    ..Prostate-specific antigen screening has led to an increase in the diagnosis and treatment of localized prostate cancer. However, the role of active treatment of low- and intermediate-risk disease in elderly men is controversial...
  18. ncbi Early stopping designs based on progression-free survival at an early time point in the initial cohort
    Samuel Litwin
    Biostatistics Facility, Population Science Division, Fox Chase Cancer Center, 333 Central Avenue, Philadelphia, PA 19111, USA
    Stat Med 26:4400-15. 2007
    ..No distributional assumptions are needed other than the binomial, so the design provides rigorous power analysis for this type of study. Tables of optimal designs are supplied for a broad range of requirements...
  19. ncbi New paradigm in dose-finding trials: patient-specific dosing and beyond phase I
    Andre Rogatko
    Winship Cancer Institute, Atlanta, Georgia 30322, USA
    Clin Cancer Res 11:5342-6. 2005
    ..These examples should be interpreted as an enticement for the development of new methods to implement the proposed new paradigm...
  20. ncbi Cutaneous metastases from genitourinary malignancies
    Thomas J Mueller
    Department of Urological Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 63:1021-6. 2004
    ..Definitive diagnosis requires an index of suspicion and skin biopsy. Cutaneous metastases from urologic malignancies are associated with a poor prognosis...
  21. ncbi Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma
    Natalie C Twine
    Discovery Medicine, Wyeth Research, Cambridge, Massachusetts 02140, USA
    Cancer Res 63:6069-75. 2003
    ..The present findings have important implications for diagnosis and future clinical pharmacogenomic studies of antitumor therapies...
  22. ncbi Boosting bioavailability of topotecan: what do we gain?
    Gary Hudes
    J Clin Oncol 20:2918-9. 2002
  23. ncbi Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents
    Gregory R Pond
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Ave, Ste 5 718, Toronto, Ontario, M5G 2M9, Canada
    J Clin Oncol 26:1324-30. 2008
    ....